Abstract
Despite advances in epilepsy therapeutics, some physicians feel uncomfortable with newer antiepileptic drugs (AEDs) due to difficulty in promptly obtaining blood levels to guide medication adjustment, and even when levels for newer AEDs are obtained, many practitioners feel they are not very useful. Lacking confidence in AEDs whose levels that cannot readily or expeditiously be measured, many clinicians share uncertainty about proper use of the newer AEDs and monitoring AED administration. Similarly, some epilepsy patients inflate the importance of AED blood level monitoring, feeling that blood levels falling within traditionally therapeutic ranges are a fail-safe for seizure control, regardless of their compliance or personal behavior aggravating seizure burden, such as poor sleep or use of illicit substances. This review examines the elusive concept of therapeutic AED blood levels and potential uses and abuses of blood level monitoring, reinforcing appropriate uses for blood levels to ensure compliance and adjust for altered AED pharmacokinetics in the context of aging and disease states, pregnancy, or drug interactions.
Keywords: Epilepsy, antiepileptic drugs, blood levels, monitoring
Current Neuropharmacology
Title: Monitoring Antiepileptic Drugs: A Level-Headed Approach
Volume: 7 Issue: 2
Author(s): Erik K. St. Louis
Affiliation:
Keywords: Epilepsy, antiepileptic drugs, blood levels, monitoring
Abstract: Despite advances in epilepsy therapeutics, some physicians feel uncomfortable with newer antiepileptic drugs (AEDs) due to difficulty in promptly obtaining blood levels to guide medication adjustment, and even when levels for newer AEDs are obtained, many practitioners feel they are not very useful. Lacking confidence in AEDs whose levels that cannot readily or expeditiously be measured, many clinicians share uncertainty about proper use of the newer AEDs and monitoring AED administration. Similarly, some epilepsy patients inflate the importance of AED blood level monitoring, feeling that blood levels falling within traditionally therapeutic ranges are a fail-safe for seizure control, regardless of their compliance or personal behavior aggravating seizure burden, such as poor sleep or use of illicit substances. This review examines the elusive concept of therapeutic AED blood levels and potential uses and abuses of blood level monitoring, reinforcing appropriate uses for blood levels to ensure compliance and adjust for altered AED pharmacokinetics in the context of aging and disease states, pregnancy, or drug interactions.
Export Options
About this article
Cite this article as:
St. Louis K. Erik, Monitoring Antiepileptic Drugs: A Level-Headed Approach, Current Neuropharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157015909788848938
DOI https://dx.doi.org/10.2174/157015909788848938 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Drug Delivery Across the Blood-Brain Barrier
Current Nanoscience Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Anticonvulsant and Antitubercular Activities of 6-Phenyl/Biphenyl-4-yl-2- [2-(pyridin-2-ylamino)-ethyl]- and 6-(Biphenyl-4yl)-2-(2N-subtituted amin- 1-yl)-ethyl derivatives of 4,5-dihydropyridazin-3(2H)-one
Letters in Drug Design & Discovery Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design Bispidine as a Privileged Scaffold
Current Topics in Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Preserving Brain Function During Development and Aging with Erythropoietin
Current Neurovascular Research Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Current Drug Targets Neurochemical Imbalance in Epilepsy from Animal Model to Human
Current Psychopharmacology Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Teratogenic Potential of Atypical Antipsychotic Drugs, Quetiapine and Aripiprazole in Rats
Current Psychopharmacology Structurally Unprecedented Metabolites from Marine Sponges
Current Organic Chemistry